Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide in Overweight Patients With Compensated Cirrhosis and Portal Hypertension
NCT07797101Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Sep 2026
- Primary completion
- May 2029
01
Overview
Open-label, single-arm trial of mazdutide in Cirrhosis and Portal Hypertension (PH), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Percentage Change in Hepatic Venous Pressure Gradient at 16 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mazdutide
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on NCT07797101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797101.